The CGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CGEN Detailed Price Forecast - CNN Money||View CGEN Detailed Summary - Google Finance|
|View CGEN Detailed Summary - Yahoo! Finance||View CGEN Stock Research & Analysis - Zacks.com|
|View CGEN Trends & Analysis - Trade-Ideas||View CGEN Major Holders - Barrons|
|View CGEN Call Transcripts - NASDAQ||View CGEN Breaking News & Analysis - Seeking Alpha|
|View CGEN Annual Report - CompanySpotlight.com||View CGEN OTC Short Report - OTCShortReport.com|
|View CGEN Fundamentals - TradeKing||View CGEN SEC Filings - Bar Chart|
|View Historical Prices for CGEN - The WSJ||View Performance/Total Return for CGEN - Morningstar|
|View the Analyst Estimates for CGEN - MarketWatch||View the Earnings History for CGEN - CNBC|
|View the CGEN Earnings - StockMarketWatch||View CGEN Buy or Sell Recommendations - MacroAxis|
|View the CGEN Bullish Patterns - American Bulls||View CGEN Short Pain Metrics - ShortPainBot.com|
|View CGEN Stock Mentions - StockTwits||View CGEN Stock Mentions - PennyStockTweets|
|View CGEN Stock Mentions - Twitter||View CGEN Investment Forum News - Investor Hub|
|View CGEN Stock Mentions - Yahoo! Message Board||View CGEN Stock Mentions - Seeking Alpha|
|View Insider Transactions for CGEN - SECform4.com||View Insider Transactions for CGEN - Insider Cow|
|View CGEN Major Holdings Summary - CNBC||View Insider Disclosure for CGEN - OTC Markets|
|View Insider Transactions for CGEN - Yahoo! Finance||View Institutional Holdings for CGEN - NASDAQ|
|View CGEN Stock Insight & Charts - FinViz.com||View CGEN Investment Charts - StockCharts.com|
|View CGEN Stock Overview & Charts - BarChart||View CGEN User Generated Charts - Trading View|
HOLON, Israel, Sept. 20, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein, in patients with advanced solid tumors. Under the terms of the collaboration and license agreement, Compugen is entitled to a milestone payment of $7.8 million at first patient dosing.
Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?
Posted on Friday September 14, 2018
Anyone researching Compugen Ltd (NASDAQ:CGEN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there areRead More...
Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial
Posted on Friday September 07, 2018
HOLON, Israel, Sept. 7, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG. PVRIG is a novel immune checkpoint identified by Compugen using its computational discovery capabilities. "Dosing the first patient with COM701, a first-in-class drug opportunity targeting a novel immune checkpoint we identified with our computational predictive platform, is a landmark event for us.
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Posted on Wednesday September 05, 2018
HOLON, Israel, Sept. 5, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Jean-Pierre Bizzari, M.D., formerly Executive Vice President and Global Head of Oncology at Celgene Corporation, to its Board of Directors. "I am delighted to welcome Jean-Pierre to Compugen's Board," said Paul Sekhri, Chairman of the Board. "I am confident that his extensive experience in oncology drug development will prove invaluable to Compugen.